Numerous studies have shown that SMARCA4 may influence the development of AMI by controlling vascular smooth muscle [24, 25].In the current research, there was no substantial association between the present dyslipidemia in CAD patients and SMARCA4 rs1122608 SNP genotypes (Table 6). Here, SMARCA4 is linked to metabolic syndrome.